Sequencing beyond the second-line setting in metastatic colorectal cancer: further observations
Grothey, A.; Marshall, J.L.; Bekaii-Saab, T.
Clinical Advances in Hematology and Oncology H&o 17 Suppl 7(3): 16-18
2019
ISSN/ISBN: 1543-0790 PMID: 31730592 Document Number: 699123
Document emailed within 1 workday
Related Documents
Lee, J.J.; Sun, W. 2016: Options for Second-Line Treatment in Metastatic Colorectal Cancer Clinical Advances in Hematology and Oncology: H&o 14(1): 46-54Karacetin, D.; Yalcin, B.; Okten, B.; Ozturk, S.; Maral, O.; Incekara, O. 2009: Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 14(4): 605-608
2013: Danitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer Prescrire International 22(138): 120
Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. 2003: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer Research 23(2c): 1951-1954
Li, J.; Xu, J-Ming.; Li, J.; Zhang, X-Dong.; Bai, Y.; Chu, Y-Ping.; Wang, Y-Hua.; Liu, D-Qi.; Jin, M-Lin.; Shen, L. 2008: Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer Zhonghua Zhong Liu Za Zhi 30(3): 225-227
Hsiao, S-Chuan.; Lin, J-Fen.; Chuang, M-Te.; Lee, Y-An.; Wu, D-Long. 2009: Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer International Surgery 94(4): 298-303
Van Cutsem, E.; Blijham, G.H. 1999: Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group Seminars in Oncology 26(1 Suppl. 5): 13-20
Yang, J.-L.; Jackson, P.; Yu, Y.; Russell, P.J.; Markovic, B.; Crowe, P.J. 2002: Expression of the KAI1 metastasis suppressor gene in non-metastatic versus metastatic human colorectal cancer Anticancer Research 22(6a): 3337-3342
Lin, J.C.; Cheng, J.Y.; Meng, C.L. 1992: An animal model for colon cancer metastases to the lung and establishment of metastatic cancer cell line Journal of the Formosan Medical Association 91(Suppl 1): S34-S38
Watanabe, T.; Sawada, T.; Kubota, Y.; Ooya, M.; Masaki, T.; Sameshima, S.; Shinozaki, M.; Tsuno, N.; Uchiyama, M.; Sakaguchi, M. 1992: Continuous intra-arterial infusion chemotherapy in colorectal cancer patients with nonresectable metastatic liver cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(10 Suppl): 1515-1518
Bartlett, D.L.; Chu, E. 2012: Can metastatic colorectal cancer be cured? Oncology 26(3): 266-275
Saltz, L.B. 2014: Management of metastatic colorectal cancer Oncology 28(10): 841
Marshall, J.L. 2014: Maintenance therapy in metastatic colorectal cancer Clinical Advances in Hematology and Oncology: H&o 12(6): 388-390
Govindarajan, R. 2000: Irinotecan and thalidomide in metastatic colorectal cancer Oncology 14(12 Suppl. 13): 29-32
Grenon, N.N. 2011: The evolving care of metastatic colorectal cancer Oncology 25(7 Suppl Nurse Ed): 44-45
Katsumoto, Y.; Aritake, N.; Endoh, A. 2010: The efficacy of cetuximab for metastatic colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(12): 2523-2525
Turja, J.; Grothey, A. 2008: Individualizing therapy for metastatic colorectal cancer Oncology 22(13): 1479-1481
Patanaphan, V.; Salazar, O.M. 1993: Colorectal cancer: metastatic patterns and prognosis Southern Medical Journal 86(1): 38-41
Tanada, M.; Nakata, M.; Kubo, Y.; Saeki, H.; Aogi, K.; Ishizaki, M.; Kurita, A.; Takashima, S. 2002: Pulmonary resection for metastatic colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(12): 2135-2137
Jakovljevic, M.; Gutzwiller, F.; Schwenkglenks, M.; Milovanovic, O.; Rancic, N.; Varjacic, M.; Stojadinovic, D.; Dagovic, A.; Matter-Walstra, K. 2014: Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma Journal of BUON: Official Journal of the Balkan Union of Oncology 19(4): 1111-1120